逍遥散治疗焦虑症的有效性与安全性:系统评价、荟萃分析与试验序贯分析
该系统评价纳入14项随机对照试验共1256例焦虑患者,比较逍遥散(单用或联合抗焦虑药)与抗焦虑药的疗效与安全性。荟萃分析显示,逍遥散联合抗焦虑药的疗效显著优于单用抗焦虑药(RR=1.19),且不良事件率显著更低(RR=0.44);逍遥散单用疗效也显著优于抗焦虑药(RR=5.41),但不良事件无统计学差异。试验序贯分析证实上述结果。
要点
- 逍遥散联合抗焦虑药治疗焦虑的疗效显著优于单用抗焦虑药,且不良事件更少。
- 逍遥散单用治疗焦虑的疗效显著优于抗焦虑药,但不良事件需更多大样本研究验证。
- 多数纳入研究存在高偏倚风险,证据质量需谨慎解读。
核心结论
- 逍遥散联合抗焦虑药治疗焦虑安全有效。
- 逍遥散单用治疗焦虑有效,但需更多大规模研究探讨不良事件。
研究设计与样本
- 系统评价与荟萃分析,检索12个数据库从建库至2023年8月10日。
- 纳入14项随机对照试验,共1256例焦虑患者。
- 8项研究评估为高偏倚风险,6项为中等偏倚风险。
- 3项试验比较口服逍遥散与抗焦虑药,11项试验比较口服逍遥散联合抗焦虑药与单用抗焦虑药。
主要发现
- 逍遥散联合抗焦虑药组疗效显著高于单用抗焦虑药组(RR=1.19;95%CI:[1.13, 1.26];p<0.00001;I2=0)。
- 逍遥散联合抗焦虑药组不良事件率显著低于单用抗焦虑药组(RR=0.44;95%CI:[0.28, 0.82];p=0.001<0.05;I2=13)。
- 逍遥散单用组疗效显著高于单用抗焦虑药组(RR=5.41;95%CI:[2.23, 13.11];p<0.0001;I2=0)。
- 逍遥散单用组与单用抗焦虑药组不良事件无统计学差异,尽管逍遥散单用组不良事件发生率更低。
- 试验序贯分析证实上述发现。
关键数值与推荐
- 疗效比较采用相对危险度(RR)及95%置信区间(CI)。
- 逍遥散联合抗焦虑药 vs 单用抗焦虑药:疗效RR=1.19(95%CI:[1.13, 1.26];p<0.00001;I2=0);不良事件RR=0.44(95%CI:[0.28, 0.82];p=0.001<0.05;I2=13)。
- 逍遥散单用 vs 单用抗焦虑药:疗效RR=5.41(95%CI:[2.23, 13.11];p<0.0001;I2=0);不良事件无统计学差异。
临床怎么用
- 对于焦虑患者,可考虑逍遥散联合抗焦虑药以提高疗效并减少不良事件。
- 逍遥散单用可作为焦虑治疗的选择,但需监测不良事件并期待更多研究。
- 临床决策时应考虑纳入研究的高偏倚风险,谨慎解读证据。
局限性
- 多数纳入研究(8/14)存在高偏倚风险。
- 逍遥散单用与抗焦虑药的不良事件比较无统计学差异,需更多大规模研究。
- 未报告其他局限性如异质性、发表偏倚等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Introduction: The effectiveness and safety of the Chinese herbal medicine (CHM) Xiao Yao San (XYS) used for treating anxiety disorders are still unknown. Thus, we conducted this systematic review with meta-analysis and trial sequential analysis (TSA) to determine its safety and efficacy. Methods: We searched 12 databases for relevant studies from the inception of each database till 10 August 2023. We selected randomized controlled trials to compare the efficacy and safety of XYS (including XYS only and XYS + anxiolytics) to those of anxiolytics in patients with anxiety. Results: We found 14 trials with 1,256 patients in total that met the requirements for inclusion. We assessed the majority of studies (8 out of 14) as being at high risk of bias; 6 were assessed as having a moderate risk of bias. Three trials compared oral XYS to anxiolytic medication, and 11 trials compared oral XYS plus anxiolytics to anxiolytic treatment alone. The pooled results showed that the efficacy of treatment in the XYS + anxiolytics groups was significantly higher than that of the anxiolytics alone group (RR = 1.19; 95% CI: [1.13, 1.26]; p < 0.00001; I2 = 0) and the adverse event rates in the XYS + anxiolytics groups were significantly lower than those in the anxiolytics alone group (RR = 0.44; 95% CI: [0.28, 0.82]; p = 0.001 < 0.05; I2 = 13). The efficacy of treatment in the XYS alone groups was also significantly higher than that of the anxiolytics alone groups (RR = 5.41; 95% CI: [2.23, 13.11]; p < 0.0001; I2 = 0). However, there was no statistical difference between the adverse events of the XYS alone group and the anxiolytics alone group, although the incidence of adverse events in the XYS alone group was lower than that in the anxiolytics alone group. The results of the TSA confirmed the above findings. Conclusion: The use of XYS combined with anxiolytics for treating anxiety was found to be safe and effective. However, although XYS alone is effective in the treatment of anxiety disorder, more large-scale research is needed to investigate adverse events. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=350358, identifier CRD42022350358.
引用
- Wang Y, Chen X, Wei W, et al. Efficacy and safety of the Chinese herbal medicine Xiao Yao San for treating anxiety: a systematic review with meta-analysis and trial sequential analysis. Front Pharmacol. 2023. PMID: 37905203. doi:10.3389/fphar.2023.1169292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。